Renub Research has recently published a report named “Global Diabetes Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2030,” providing a detailed industry analysis that consists of market share insights. Furthermore, the report encompasses a study of competitors and regions and the recent growth in the Global Diabetes Drugs Market.

 

Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/diabetes-drug-market-p.php

 

Global Diabetes Drugs Market is foreseen to expand at a CAGR of 5.49% from 2023 to 2030

 

Diabetes is a global epidemic with significant demand for diabetes drugs. According to World Health Organisation (WHO), the prevalence of diabetes is increasing worldwide, with an estimated 537 million adults affected in 2022, projected to rise to 783 million by 2045. This chronic disease affects the body energy metabolism and can lead to severe complications such as heart disease, stroke, blindness, kidney failure, and amputations. However, with proper management, individuals with diabetes can lead long and healthy lives.

 

With various types of diabetes, including type 1, type 2, and gestational diabetes, it affects the body’s ability to regulate blood sugar levels. Type 1 diabetes requires lifelong insulin therapy, while type 2 diabetes is often associated with insulin resistance and lifestyle factors. Gestational diabetes occurs during pregnancy but can increase the risk of type 2 diabetes later in life. Common symptoms include excessive thirst, frequent urination, weight loss, and fatigue. Badly managed diabetes can lead to momentous complications. Management involves lifestyle modifications and medications such as insulin and oral antidiabetic drugs. Regular monitoring, check-ups, and education are essential for effective diabetes management.

 

The future of the global diabetes drugs market looks promising due to factors like increasing prevalence of type 2 diabetes, advancements in research and development, personalized medicine approaches, improved awareness and education, digital health technologies, collaborations, favorable reimbursement policies, government initiatives, and increased healthcare spending in emerging markets. These factors will drive the demand for effective treatments, innovation, optimized therapeutic outcomes, improved diagnosis and treatment rates, real-time monitoring, self-care, treatment optimization, and better access to healthcare services and affordable medications for effective diabetes management.

 

 Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=diabetes-drug-market-p.php

 

Type 1 Diabetes dominates the global diabetes drugs market.

 

According to the Lancet Diabetes & Endocrinology, global type 1 diabetes (T1D) cases are projected to increase from 8.4 million in 2021 to 13.5-17.4 million by 2040. The dominance of type 1 diabetes in the global diabetes drugs market is attributed to its chronic nature, requiring lifelong insulin treatment, and creating a consistent demand for diabetes drugs. The intensive management and monitoring of type 1 diabetes further contribute to the reliance on medication. The lower prevalence of type 1 diabetes compared to type 2 diabetes allows for a more targeted market for specialized diabetes drugs.

 

Disease Type – Global Diabetes Drug Market has been covered from 2 viewpoints:

 

1.    Type 1 Diabetes Drug Market

2.    Type 2 Diabetes Drug Market

 

Insulin dominates the global diabetes drug market by managing type 1 diabetes and being used for some with type 2 diabetes.

 

The high prevalence of both diabetes types drives the significant demand for insulin. Its longstanding effectiveness, reputation, and trust among healthcare professionals and patients make it a preferred treatment option. Insulin continuous need for managing chronic diabetes and its advancements in formulations and delivery methods, including analogs, offer tailored treatment options. The existing manufacturing and distribution infrastructure, along with patent protection and regulatory requirements, create barriers for new entrants, solidifying insulin’s dominant position in the global diabetes drugs market.

 

Therapy –Global Diabetes Drugs Market have been covered from 3 viewpoints:

 

Oral

Injection

Insulin

 

DPP-IV inhibitors’ leadership in the global diabetes drugs market is attributed to their flexibility, extensive research, and medical association endorsements.

 

DPP-IV inhibitors effectively manage type 2 diabetes by regulating blood

sugar levels through increased insulin secretion and reduced glucagon levels. With oral administration, favorable side effects, and flexibility in treatment approaches, they are preferred by healthcare professionals. Extensive research has resulted in a diverse portfolio, allowing tailored treatment options. Supported by clinical evidence and endorsed by medical associations, DPP-IV inhibitors lead the global diabetes drugs market for type 2 diabetes management.

 

Oral- Global Diabetes Drugs Market have been covered from 5 viewpoints.

 

Oral (DPP) IV inhibitor

SGLT – 2

Alpha Glucosidase Inhibitor

Biguanide

Others Oral Drug

 

Glucagon-like peptide (GLP-1) agonists’ hegemony in the global diabetes drug market.

 

Glucagon-like peptide (GLP-1) agonists offer additional benefits such as weight loss, appetite reduction, and improved cardiovascular health, making them preferred for comprehensive diabetes management. With various administration options available, including injections and oral medications, GLP-1 agonists provide flexibility and enhance patient compliance. Extensive research and development efforts have resulted in a diverse range of drugs within this class, enabling personalized treatment plans. Clinical trials and real-world evidence consistently demonstrate the efficacy and safety of GLP-1 agonists, solidifying their widespread adoption.

 

Injection – Global Diabetes Drugs Market is covered from 2 viewpoints.

 

Glucagon-like peptide (GLP) 1 agonist

Amylin receptor agonist

 

Long-acting insulinhas significant share in the global diabetes drugs market is due to its ability to provide steady and prolonged insulin release for stable blood sugar control.

 

Long-acting insulin’s flexible dosing options cater to individual patient needs, either as a standalone therapy or in combination with other drugs. The long history of safe and effective use has instilled confidence among healthcare professionals and patients. Also, the availability of various formulations, including improved insulin analogs, enhances convenience and administration. The high prevalence of diabetes, especially type 2, fuels the demand for long-acting insulin, while its well-established manufacturing and distribution infrastructure, along with patent protection and regulatory requirements, present barriers to new competitors, consolidating its significant market share.

 

Insulin – Global Diabetes Drugs Market is covered from 4 viewpoints.

 

Rapid – Acting Insulin

Long – Acting Insulin

Premixed Insulin

Other Insulin

 

United States has the highest share in the global diabetes drugs market.

 

The United States takes the lead in the global diabetes drugs market, primarily due to its substantial diabetes prevalence, advanced healthcare infrastructure, thriving pharmaceutical industry, robust research and development capabilities, prominent presence of pharmaceutical companies and healthcare providers, favorable reimbursement policies, and comprehensive insurance coverage.

According to the National Diabetes Statistics Reportin 2022, approximately 37.3 million Americans, accounting for around 11.3% of the population, are living with diabetes, and the country exhibits a significant demand for diabetes drugs. These factors collectively enable patients in the United States to access a wide range of medications and treatment options promptly and contribute to the nation’s prominence in the global diabetes drugs market.

 

Countries-Global Diabetes Drugs Market is covered in 24 viewpoints.

 

1. United States
2. Canada
3. France
4. Germany
5. Italy
6. Spain
7. UK
8. Mexico
9. Brazil
10. Japan
11. South Korea
12. China
13. India
14. Australia
15. Vietnam
16. Malaysia
17. Indonesia
18. Philippines
19. Thailand
20. Saudi Arabia
21. Iran
22. Egypt
23. Oman
24. South Africa

 

Competitive Landscape.

 

Novo Nordisk, AstraZeneca plc, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb Co., and Novartis AG are key players in the global diabetes drug market, contributing significantly to its development and growth.

 

Company Insights:

 

•    Overview

•    Recent Development & Strategies

•    Financial Insights

 

Key Players Analysis

 

Novo Nordisk

AstraZeneca plc

Biocon

Sanofi

Eli Lilly

Johnson & Johnson

Bristol Myers Squibb Co.

Novartis AG

 

Related Reports

 

Schizophrenia Drugs Market size is projected to reach US$ 9.46 Billion by 2030

China Oncology Drugs Market size will attain a cost of US$ 42.19 Billion via 2028

Global Wound Care Market size is anticipated to be valued at US$ 30.08 Billion by 2030

Oncology Precision Medicine Market size is projected to surpass US$ 123.44 Billion by 2028

 

About the Company: 

Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

 

Media Contact:

 

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Address: 225 Kristie Ln, Roswell, GA 30076

Email: info@renub.com

LinkedIn: https://linkedin.com/company/renub-research